NO981189D0 - Fremgangsmåter for fremstilling av ikke-kovalent komplekserte og multivalente proteosom-subenhet-vaksiner - Google Patents

Fremgangsmåter for fremstilling av ikke-kovalent komplekserte og multivalente proteosom-subenhet-vaksiner

Info

Publication number
NO981189D0
NO981189D0 NO981189A NO981189A NO981189D0 NO 981189 D0 NO981189 D0 NO 981189D0 NO 981189 A NO981189 A NO 981189A NO 981189 A NO981189 A NO 981189A NO 981189 D0 NO981189 D0 NO 981189D0
Authority
NO
Norway
Prior art keywords
ultrafiltration
multivalent
proteosomeamphiphilic
diafiltration
vaccine
Prior art date
Application number
NO981189A
Other languages
English (en)
Other versions
NO981189L (no
NO320074B1 (no
Inventor
George H Lowell
Wendell D Zollinger
James F Woods
Original Assignee
Us Army Med Res Mat Command
George H Lowell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21707938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO981189(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Army Med Res Mat Command, George H Lowell filed Critical Us Army Med Res Mat Command
Publication of NO981189D0 publication Critical patent/NO981189D0/no
Publication of NO981189L publication Critical patent/NO981189L/no
Publication of NO320074B1 publication Critical patent/NO320074B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/008—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO19981189A 1995-09-18 1998-03-17 Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten. NO320074B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US385995P 1995-09-18 1995-09-18
PCT/US1996/015002 WO1997010844A1 (en) 1995-09-18 1996-09-18 Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Publications (3)

Publication Number Publication Date
NO981189D0 true NO981189D0 (no) 1998-03-17
NO981189L NO981189L (no) 1998-05-14
NO320074B1 NO320074B1 (no) 2005-10-17

Family

ID=21707938

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981189A NO320074B1 (no) 1995-09-18 1998-03-17 Fremgangsmater for fremstilling av proteosom-amfifil-determinant vaksine, samt multivalent vaksine fremstilt i folge fremgangsmaten.

Country Status (20)

Country Link
US (1) US6476201B1 (no)
EP (1) EP0854729B2 (no)
JP (2) JP4033489B2 (no)
KR (1) KR19990045763A (no)
CN (1) CN1211192A (no)
AT (1) ATE261313T1 (no)
BR (1) BR9610484A (no)
CA (1) CA2232410C (no)
CZ (1) CZ298460B6 (no)
DE (1) DE69631835T3 (no)
DK (1) DK0854729T3 (no)
EA (1) EA199800208A1 (no)
ES (1) ES2217325T5 (no)
HU (1) HUP9901577A3 (no)
IL (1) IL123720A (no)
MX (1) MX9802128A (no)
NO (1) NO320074B1 (no)
PL (1) PL325604A1 (no)
PT (1) PT854729E (no)
WO (1) WO1997010844A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US8007815B1 (en) * 1998-05-29 2011-08-30 Novartis Ag Combination meningitidis B/C vaccines
CN100392082C (zh) 1999-04-30 2008-06-04 启龙股份公司 保守的奈瑟球菌抗原
DK2270173T3 (en) * 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
US6743900B2 (en) 2000-02-15 2004-06-01 Id Biomedical Corporation Of Quebec Proteosome influenza vaccine
EP1721618A3 (en) * 2000-02-15 2007-01-10 ID Biomedical Corporation of Quebec Proteosome influenza vaccine composition
MXPA02008314A (es) 2000-02-28 2002-12-09 Chiron Spa Expresion heterologa de proteinas de neisseria.
MXPA03008154A (es) * 2001-03-09 2004-11-12 Id Biomedical Corp Quebec Novedoso adyuvante de vacuna de proteosoma-liposacarido.
WO2004015099A2 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
CA2501812C (en) 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
JP2007505836A (ja) * 2003-09-15 2007-03-15 アイディー バイオメディカル コーポレイション オブ ケベック 麻疹サブユニットワクチン
ES2615169T3 (es) * 2003-10-22 2017-06-05 Id Biomedical Corporation Of Quebec Composiciones y procedimientos de activación de la inmunidad innata y alérgica
RU2387453C2 (ru) 2004-06-25 2010-04-27 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Композиции и способы лечения неврологических нарушений
JP2008505114A (ja) * 2004-06-30 2008-02-21 アイディー バイオメディカル コーポレイション オブ ケベック コロナウイルス感染を処置するためのワクチン組成物
US7552948B2 (en) 2006-03-29 2009-06-30 Tokai Rubber Industries, Ltd. Quick connector
CN110064053A (zh) * 2006-08-07 2019-07-30 哈佛大学校长及研究员协会 蛋白质基质疫苗及这种疫苗的制备和给药方法
MX2009001412A (es) 2006-08-07 2009-04-24 Harvard College Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
JP2010502425A (ja) * 2006-08-30 2010-01-28 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション 膜を評価するシステム及び方法並びに膜濾過装置
AU2009262893B2 (en) * 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
US20120231086A1 (en) * 2009-09-09 2012-09-13 Killen Kevin P Protein matrix vaccines of improved immunogenicity
EP4183408A1 (en) * 2014-09-24 2023-05-24 The United States of America as Represented by The Secretary of the Navy Combined enterotoxigenic escherichia coli and shigella recombinant
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU1522494C (ru) * 1987-06-16 1994-11-15 Научно-производственное объединение "Иммунопрепарат" Способ получения инактивированной вакцины гриппа
RU2023448C1 (ru) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
ES2070312T5 (es) * 1988-12-19 2003-05-16 American Cyanamid Co Vacuna de proteina de membrana exterior meningococica de clase 1.
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
CA2139517A1 (en) * 1992-07-20 1994-02-03 Paul M. Keller Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US6743900B2 (en) * 2000-02-15 2004-06-01 Id Biomedical Corporation Of Quebec Proteosome influenza vaccine

Also Published As

Publication number Publication date
HUP9901577A3 (en) 2000-03-28
KR19990045763A (ko) 1999-06-25
EP0854729B2 (en) 2008-10-22
CA2232410C (en) 2003-06-17
DK0854729T3 (da) 2004-07-12
WO1997010844A1 (en) 1997-03-27
US6476201B1 (en) 2002-11-05
IL123720A (en) 2002-02-10
CA2232410A1 (en) 1997-03-27
EP0854729A4 (en) 2000-02-02
HUP9901577A2 (hu) 1999-08-30
EA199800208A1 (ru) 1998-10-29
CZ298460B6 (cs) 2007-10-10
JP4033489B2 (ja) 2008-01-16
ES2217325T3 (es) 2004-11-01
EP0854729A1 (en) 1998-07-29
DE69631835D1 (de) 2004-04-15
JP2004099619A (ja) 2004-04-02
ATE261313T1 (de) 2004-03-15
BR9610484A (pt) 2001-09-11
CN1211192A (zh) 1999-03-17
US20020164357A1 (en) 2002-11-07
NO981189L (no) 1998-05-14
IL123720A0 (en) 1998-10-30
EP0854729B1 (en) 2004-03-10
DE69631835T2 (de) 2005-02-10
PL325604A1 (en) 1998-08-03
NO320074B1 (no) 2005-10-17
CZ81998A3 (cs) 1998-10-14
PT854729E (pt) 2004-08-31
JP2000507913A (ja) 2000-06-27
ES2217325T5 (es) 2009-04-01
MX9802128A (es) 1998-11-29
DE69631835T3 (de) 2009-03-05

Similar Documents

Publication Publication Date Title
NO981189L (no) FremgangsmÕter for fremstilling av ikke-kovalent komplekserte og multivalente proteosom-subenhet-vaksiner
Walker New strategies for using mucosal vaccination to achieve more effective immunization
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
EP0777490B1 (en) Mutant enterotoxin effective as a non-toxic oral adjuvant
GR3033469T3 (en) Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci.
EP1297844A3 (en) Multicomponent meningococcal vaccine
HU185404B (en) Process for preparing pertussis toxoide
CA2277141A1 (en) Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure
ES2007720A6 (es) Procedimiento de obtencion de una vacuna a base de flagelo bacterial.
Amend et al. Some factors affecting the potency of Yersinia ruckeri bacterins
SE9003278D0 (sv) Foerfarande respektive anlaeggning foer beredning av en medicinsk loesning, t ex en dialysloesning
AU6721801A (en) The use of plant oil-bodies in vaccine delivery systems
AU2027797A (en) Method of producing immunogenic products and vaccines
CH662056A5 (fr) Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies.
EP0082072B1 (fr) Procédé de production d'un vaccin biochimique contre les fièvres à salmonelles
ATE199059T1 (de) Herstellung eines tetanusimpfstoffes
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
Rappaport et al. Development of a purified cholera toxoid. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen
IT1206250B (it) Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
WO2003073984A3 (en) Tat as an immunogen
SU1725904A1 (ru) Способ получени бруцеллезной вакцины из штамма 82
RU93052669A (ru) Способ получения специфического лактоглобулина
RU97115149A (ru) Способ вакцинации против вирусного гепатита в
Asada et al. Arita, M. see Nomoto, A., 134 Arrhenius, T. see Satterthwait, AC, 99 Artamonov, AF see Berezin, VE, 450 Arya, SC Continuing global polio
Shewen et al. Process for the production of vaccine for prevention of Pasteurella haemolytica pneumonia in bovine

Legal Events

Date Code Title Description
MK1K Patent expired